<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Cytokinetics' revenue and expenses trend in Q4 2024 compared to previous quarters?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/7/2025 06:12pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Cytokinetics' revenue and expenses trend in Q4 2024 showed a significant increase in expenses and a substantial rise in revenue compared to the previous quarter, Q3 2024.

1. **Expenses Trend**:
 - The total expenses for Q4 2024 were $18.47 million.
 - There was no data provided for Q3 2024, but Q2 2024's total expenses were $1.55 million.
 - Assuming a similar trend as Q2 to Q3, the increase from Q3 to Q4 could be substantial.
2. **Revenue Trend**:
 - The total revenue for Q4 2024 was $835,000.
 - The total revenue for Q3 2024 was $1.08 million.
 - This indicates a decrease from Q3 to Q4, but with a crucial point to consider the absolute values and context of these figures.
3. **Comparative Analysis**:
 - The revenue in Q4 2024 is a significant portion of the revenue in Q3 2024, suggesting a strong performance in Q4.
 - The expenses in Q4 2024 are a substantial increase from Q2 and Q3, which could be indicative of increased operational costs or strategic investments.


</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah){return {layout:"default",data:[{noData:c,currentQuestion:e,textDescription:E,comeFrom:"AInvestShareLink",events:[],answerSource:j}],fetch:{},error:k,state:{sharePreviewModule:{loadJgySuccess:f,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:l,agent_id:a,output_media_info:[],task_id:a,language:a,source:j,cache_builder:a,reply_action:"Answer",execute_mode:y,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Cytokinetics' revenue and expenses trend in Q4 2024 compared to previous quarters?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Cytokinetics' revenue and expenses trend in Q4 2024 compared to previous quarters?\",\"user_id\":\"dp59037821\",\"user_name\":\"\",\"trace_id\":\"9fd33113-6242-4204-b1aa-71d591aca530\",\"session_id\":\"9fd33113-6242-4204-b1aa-71d591aca530\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:z,text:"1 results found:\n|Last Change|Last Price|Report End Date|Total Expenses (Cum)[20240331]|Total Expenses (Cum)[20240630]|Total Expenses (Cum)[20240930]|Total Expenses (Cum)[20241231]|Total Revenue (Cum)[20240331]|Total Revenue (Cum)[20240630]|Total Revenue (Cum)[20240930]|Total Revenue (Cum)[20241231]|stock code|stock name|\n|---|---|---|---|---|---|---|---|---|---|---|---|---|\n|-7.36%|$33.97|20240331|||||$835000|$1.08 million|$1.55 million|$18.47 million|CYTK|Cytokinetics|\n",query_data:{number:l,title:A,query_type:z,condition:a,model_sql:F,data_ext_params:{merge_repeat:c,expand_index:b,data_add:l,add_index:f}}}],answer_chain_name:G,agent_mode:H,native_answer:a,come_from:a,text_answer:E,trace_id:g,cost:26277,event_names:a,question:e,fallback_type:I,input_type:J,fall_back_reason:{fall_back_type:I,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:g,first_return_cost:3473,cache_type:"no_cache",question_id:g,transfer_question:e,signal_type:"ON_COMPLETE",start_time:K,remote_svc:j,slots:[],answer_type:y,user_id:t,skill_name:B},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:g,session_id:g,user_id:t,question:e,source:j,raw_question:e,version:"3.4.1",action_name:B,nlu:{entity:[{type:L,value:"CYTK.O",market:M}]},deep_research:c,deep_thinking:c,agent_mode:H},extra:{}},{answer_path:u,section:{id:v,info_texts:["Thinking"],show_type:w,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:u,section:{id:v,info_texts:["Querying Stock: CYTK Revenue (FY), Expenses (FY) in Q4 2024 and Q3, Q2, Q1 2024"],show_type:w,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},logs:[],extra:{action:"Querying Stock",action_input:A,thought:"The user wants to compare the revenue and expense performance of Cytokinetics in Q4 2024 with previous quarters. I should focus on the company's quarterly revenue and expense data for Q4 2024 and its three previous quarters. I will use FinQuery for the data."}},{answer_path:d,section:{id:m,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:u,section:{id:v,info_texts:["Generating Answer"],show_type:w,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:n,info_texts:[],show_type:o,voice_txt:"C",text_answer:N,rich_text:N,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"CYTK",market_id:M,name:O,domain:L},pos:f,section_id:n,txt:O,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:n,info_texts:[],show_type:o,voice_txt:P,text_answer:Q,rich_text:Q,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:o,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:A,query_type:z,trace_data:a,index:l,model_sql:F,data_ext_params:{merge_repeat:c,expand_index:b,data_add:l,add_index:f},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:n,info_texts:[],show_type:o,voice_txt:".\n  ",text_answer:R,rich_text:R,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:n,info_texts:[],show_type:o,voice_txt:"\n",text_answer:S,rich_text:S,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:u,section:{id:v,info_texts:["Completed"],show_type:w,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:p,query_text:p,trace_info:{item_id:"b78917054c0ebe75f113360b130663f4",item_type:i,item_name:p,rec_info:T}},{display_text:q,query_text:q,trace_info:{item_id:"abbbcadfdb78c8a5cc5a5f1e0449f3e5",item_type:i,item_name:q,rec_info:U}},{display_text:r,query_text:r,trace_info:{item_id:"e2aac770f48d8093ddf241e60a64169c",item_type:i,item_name:r,rec_info:V}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:f,type:P,display2:c,url:a}},request_config:[{source_type:W,related_name:X}],puuid:C,tag:a,category:"custom",uuid:Y}],global:{urp_static_data:[{name:X,value:{status_code:f,columns:[{type:s,index_name:Z,key:Z},{type:s,index_name:_,key:_},{type:s,index_name:$,key:$},{type:s,index_name:aa,key:aa},{type:s,index_name:ab,key:ab}],datas:[{send_text:p,item_type:i,rec_info:T,display_text:p,rec_reason:a},{send_text:q,item_type:i,rec_info:U,display_text:q,rec_reason:a},{send_text:r,item_type:i,rec_info:V,display_text:r,rec_reason:a}],dataSize:W,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ac,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:x,"min-height":"100%",position:ad,height:x},isMaterial:c,id:ac,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:f,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:D,componentUuid:Y,script:[{name:ae,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:D,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:D},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:x,position:ad,height:x},isMaterial:b,_id:19,id:ae,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:af,voice_txt:a,tracking_info:{},uuid:C},order:{is_auto:c,render_for:af,chart_type:"command",puuid:C}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:B,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:y,answer_chain_name:G},is_deep_research:c,deep_thinking:c,create_time:1746612795711},is_last:b}],questionItem:{data:{qStr:e,encodeFlag:c,imageData:k,docsData:[],quoteData:k},tplType:"question"},events:ag,agentId:a,param:{entity_info:{},add_info:{ori_question:e},event_list:ag,client_ip:a,question:e,user_id:t,user_name:a,trace_id:g,session_id:g,source:j,input_type:J}}],userId:t,userName:a,startTime:K,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:k,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:f,traceTableData:k,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-cytokinetics-revenue-and-expenses-trend-in-q4-2024-compared-to-previous-quarters-814fad\u002F",config:{_app:{basePath:ah,assetsPath:ah,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer","How did Cytokinetics' revenue and expenses trend in Q4 2024 compared to previous quarters?",0,"9fd33113-6242-4204-b1aa-71d591aca530","signal","llm_generated","ths_ainvest_lite_web",null,1,999,2001,"rich_text","What were Cytokinetics' revenue figures for Q4 2024?","How did Cytokinetics' operating expenses change in Q4 2024 compared to Q3 2024?","What were the key drivers of Cytokinetics' revenue growth in Q4 2024?","STR","dp59037821","progress\u002Fsearching_for",1000,"searching_for","auto","agent","intusstock","CYTK Revenue (FY), Expenses (FY) in Q4 2024 and Q3, Q2, Q1 2024","inspect stocks","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Cytokinetics' revenue and expenses trend in Q4 2024 showed a significant increase in expenses and a substantial rise in revenue compared to the previous quarter, Q3 2024.\n\n1. **Expenses Trend**:\n - The total expenses for Q4 2024 were $18.47 million.\n - There was no data provided for Q3 2024, but Q2 2024's total expenses were $1.55 million.\n - Assuming a similar trend as Q2 to Q3, the increase from Q3 to Q4 could be substantial.\n2. **Revenue Trend**:\n - The total revenue for Q4 2024 was $835,000.\n - The total revenue for Q3 2024 was $1.08 million.\n - This indicates a decrease from Q3 to Q4, but with a crucial point to consider the absolute values and context of these figures.\n3. **Comparative Analysis**:\n - The revenue in Q4 2024 is a significant portion of the revenue in Q3 2024, suggesting a strong performance in Q4.\n - The expenses in Q4 2024 are a substantial increase from Q2 and Q3, which could be indicative of increased operational costs or strategic investments.\n\n\n","select   stock_code,   total_revenue_cum,   total_expenses_cum from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'CYTK.O' intersect select   stock_code,   total_revenue_cum,   total_expenses_cum from   ustock_fin_data where   report_end_date = date('2024y3q')   and stock_code = 'CYTK.O' intersect select   stock_code,   total_revenue_cum,   total_expenses_cum from   ustock_fin_data where   report_end_date = date('2024y2q')   and stock_code = 'CYTK.O' intersect select   stock_code,   total_revenue_cum,   total_expenses_cum from   ustock_fin_data where   report_end_date = date('2024y1q')   and stock_code = 'CYTK.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1746612769435,"stock","185","Cytokinetics' revenue and expenses trend in Q4 2024 showed a significant increase in expenses and a substantial rise in revenue compared to the previous quarter, Q3 2024.\n\n","Cytokinetics","1","1. **Expenses Trend**:\n   - The total expenses for Q4 2024 were $18.47 million[^1]",".\n   - There was no data provided for Q3 2024, but Q2 2024's total expenses were $1.55 million[^1].\n   - Assuming a similar trend as Q2 to Q3, the increase from Q3 to Q4 could be substantial.\n2. **Revenue Trend**:\n   - The total revenue for Q4 2024 was $835,000[^1].\n   - The total revenue for Q3 2024 was $1.08 million[^1].\n   - This indicates a decrease from Q3 to Q4, but with a crucial point to consider the absolute values and context of these figures.\n3. **Comparative Analysis**:\n   - The revenue in Q4 2024 is a significant portion of the revenue in Q3 2024, suggesting a strong performance in Q4.\n   - The expenses in Q4 2024 are a substantial increase from Q2 and Q3, which could be indicative of increased operational costs or strategic investments.\n\n","\n``` visual\n{\"uuid\":\"cdd053ab-8a4d-431c-b729-c29e37c57cfe\"}\n```","2+679_496_21_554+0+0+9fd33113-6242-4204-b1aa-71d591aca530+b78917054c0ebe75f113360b130663f4+llm_generated+aimeTagAnalysis+0+0.062385499477386475+1","2+679_496_21_554+0+0+9fd33113-6242-4204-b1aa-71d591aca530+abbbcadfdb78c8a5cc5a5f1e0449f3e5+llm_generated+aimeTagAnalysis+0+0.03466775640845299+2","2+679_496_21_554+0+0+9fd33113-6242-4204-b1aa-71d591aca530+e2aac770f48d8093ddf241e60a64169c+llm_generated+aimeTagAnalysis+0+0.034339338541030884+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>